1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide → 17-Cyclohexyl-18-[4-[2-morpholin-4-yl-5-(2-oxo-pyrrolidin-1-yl)-benzyloxy]-phenyl]-10,10-dioxo-10lambda6-thia-1,4,11-triaza-tricyclo[11.5.2.016,19]icosa-7,13(20),14,16(19),17-pentaene-3,12-dione

HRID 39049ノート

反応式

HRID 39049 の反応式
[CH2:1]([S:4]([NH2:7])(=[O:6])=[O:5])[CH:2]=[CH2:3].C(N=C=NCCCN(C)C)C.[CH2:19]([NH:23][C:24](=[O:76])[CH2:25][N:26]1[C:34]2[C:29](=[CH:30][CH:31]=[C:32]([C:35](NS(CC=C)(=O)=O)=[O:36])[CH:33]=2)[C:28]([CH:44]2[CH2:49][CH2:48][CH2:47][CH2:46][CH2:45]2)=[C:27]1[C:50]1[CH:55]=[CH:54][C:53]([O:56][CH2:57][C:58]2[CH:63]=[C:62]([N:64]3[CH2:68][CH2:67][CH2:66][C:65]3=[O:69])[CH:61]=[CH:60][C:59]=2[N:70]2[CH2:75][CH2:74][O:73][CH2:72][CH2:71]2)=[CH:52][CH:51]=1)[CH2:20]C=C>CN(C=O)C.CN(C)C1C=CN=CC=1.[Cl-].[Na+].O>[CH:44]1([C:28]2[C:29]3[CH:30]=[CH:31][C:32]4[C:35](=[O:36])[NH:7][S:4](=[O:6])(=[O:5])[CH2:1][CH:2]=[CH:3][CH2:20][CH2:19][NH:23][C:24](=[O:76])[CH2:25][N:26]([C:34]=3[CH:33]=4)[C:27]=2[C:50]2[CH:55]=[CH:54][C:53]([O:56][CH2:57][C:58]3[CH:63]=[C:62]([N:64]4[CH2:68][CH2:67][CH2:66][C:65]4=[O:69])[CH:61]=[CH:60][C:59]=3[N:70]3[CH2:71][CH2:72][O:73][CH2:74][CH2:75]3)=[CH:52][CH:51]=2)[CH2:49][CH2:48][CH2:47][CH2:46][CH2:45]1

参加物

7

反応物 3

HCID 159081-Ethyl-3-(3'-dimethylaminopropyl)carbodiimideHCID 14028213Prop-2-ene-1-sulfonamideHCID 59549037N-but-3-enyl-2-[3-cyclohexyl-2-[4-[2-morpholin-4-yl-5-(2-oxo-pyrrolidin-1-yl)-benzyloxy]-phenyl]-6-(prop-2-ene-1-sulfonylaminocarbonyl)-indol-1-yl]-acetamide

生成物 1

HCID 6850844117-Cyclohexyl-18-[4-[2-morpholin-4-yl-5-(2-oxo-pyrrolidin-1-yl)-benzyloxy]-phenyl]-10,10-dioxo-10lambda6-thia-1,4,11-triaza-tricyclo[11.5.2.016,19]icosa-7,13(20),14,16(19),17-pentaene-3,12-dione収率 87%

試薬・触媒・溶媒 3

HCID 142844-(Dimethylamino)pyridine触媒HCID 6228Dimethylformamide溶媒HCID 57417360Sodium chloride; water溶媒

実験手順

To a solution of intermediate 12-4 (438 mg, 0.622 mmol) and prop-2-ene-1-sulfon-amide (151 mg, 2 eq), synthesized as described in Journal of Enzyme Inhibition, 16(6), 475, 2001, in dry DMF (10 mL), were added 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDCI; 193 mg, 2 eq) and 4-dimethylaminopyridine (DMAP; 152 mg, 2 eq) at room temperature, under N2. After completion, the reaction mixture was poured into 200 mL of brine, and extracted with a mixture of ethyl acetate and THF (several times). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The obtained residue was triturated in diethylether and filtered off to afford 436 mg (87% yield) of the desired product N-but-3-enyl-2-[3-cyclohexyl-2-[4-[2-morpholin-4-yl-5-(2-oxo-pyrrolidin-1-yl)-benzyloxy]-phenyl]-6-(prop-2-ene-1-sulfonylaminocarbonyl)-indol-1-yl]-acetamide 12-5 as an off-white solid; m/z=809 (M+H)+.

後処理

  1. extractionextracted with a mixture of ethyl acetate and THF (several times)
  2. dry with materialThe combined organic layers were dried over sodium sulfate
  3. filtrationfiltered
  4. concentrationconcentrated
  5. customThe obtained residue was triturated in diethylether
  6. filtrationfiltered off

出典と根拠

ORDレコード
ord-83cf7e7cf22a48d4a6a34f37630bf8f0
出典データセット
uspto-grants-2013_09
特許番号
US08524716B2

反応ノート

読み込み中…